• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Barclays resumed coverage on Exelixis with a new price target

    9/19/25 7:43:42 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXEL alert in real time by email
    Barclays resumed coverage of Exelixis with a rating of Equal Weight and set a new price target of $40.00
    Get the next $EXEL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXEL

    DatePrice TargetRatingAnalyst
    10/21/2025$48.00Market Perform → Outperform
    Leerink Partners
    9/19/2025$40.00Equal Weight
    Barclays
    9/17/2025$40.00Equal Weight
    Barclays
    9/17/2025$47.00Buy
    Goldman
    7/8/2025$45.00 → $50.00Outperform → Sector Perform
    RBC Capital Mkts
    6/24/2025$60.00Equal-Weight → Overweight
    Stephens
    2/24/2025$36.00Overweight → Equal Weight
    Wells Fargo
    1/27/2025$30.00 → $40.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $EXEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Research & Development Aftab Dana was granted 50,673 shares, increasing direct ownership by 8% to 713,161 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    10/10/25 6:57:17 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Eckhardt Sue Gail sold $805,140 worth of shares (18,838 units at $42.74), decreasing direct ownership by 47% to 21,380 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    6/4/25 7:57:38 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Wyszomierski Jack L sold $324,683 worth of shares (7,535 units at $43.09), decreasing direct ownership by 2% to 358,882 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    6/4/25 7:57:28 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    SEC Filings

    View All

    Exelixis Inc. filed SEC Form 8-K: Leadership Update

    8-K - EXELIXIS, INC. (0000939767) (Filer)

    8/29/25 5:10:41 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Exelixis Inc.

    10-Q - EXELIXIS, INC. (0000939767) (Filer)

    7/28/25 4:31:54 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - EXELIXIS, INC. (0000939767) (Filer)

    7/28/25 4:09:07 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    5/30/24 7:50:14 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    2/22/24 5:08:50 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Edward sold $2,602,038 worth of shares (120,409 units at $21.61) and bought $2,602,038 worth of shares (120,409 units at $21.61) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    11/29/23 4:30:29 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

    DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited ("SynOx"), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the appointments of Charles "Chip" R. Romp and Tom J. Heyman to its Board of Directors. These appointments further align SynOx's business with its forward strategy as the company nears topline data for emactuzumab and continues its focus on regulatory and commercial activities. In August 2025, SynOx completed enrollment in the Phase 3 TANGENT clinical trial; topline data are expected in the first quarter of 2026. Ray Barlow, Chief Execu

    10/21/25 7:00:00 AM ET
    $AKRO
    $EXEL
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

    – Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and significantly reduced the risk of death by 20% in the intention-to-treat population – – Exelixis plans to complete its first new drug application submission for zanzalintinib in the U.S. in 2025 – Exelixis, Inc. (NASDAQ:EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met one of

    10/20/25 2:30:00 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling

    9/21/23 4:37:02 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

    7/15/22 4:38:40 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

    9/20/21 3:53:29 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exelixis upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Exelixis from Market Perform to Outperform and set a new price target of $48.00

    10/21/25 7:13:23 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays resumed coverage on Exelixis with a new price target

    Barclays resumed coverage of Exelixis with a rating of Equal Weight and set a new price target of $40.00

    9/19/25 7:43:42 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays resumed coverage on Exelixis with a new price target

    Barclays resumed coverage of Exelixis with a rating of Equal Weight and set a new price target of $40.00

    9/17/25 8:02:00 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Financials

    Live finance-specific insights

    View All

    Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

    - Total Revenues of $568.3 million, Cabozantinib Franchise U.S. Net Product Revenues of $520.0 million - - GAAP Diluted EPS of $0.65, Non-GAAP Diluted EPS of $0.75 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis continued to execute on our corporate objectives in the second quarter of 2025, delivering on key commercial, development and pipeline milestones," said Michael M. Morrissey, Ph.D., President and Chief Executiv

    7/28/25 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

    – Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2025 financial results will be released on Monday, July 28, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Eve

    7/14/25 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

    - Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 million - - GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of $0.62 - - Increasing 2025 Full Year Net Product Revenues and Total Revenues Guidance by $100 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX® d

    5/13/25 4:07:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Leadership Updates

    Live Leadership Updates

    View All

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development

    – Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company's scientific innovation and development activities – Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company's drug discovery, translational research, product development and medical affairs activities. "Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's been a key contributor to many of Exelixis' most important milestones, inclu

    8/29/25 5:47:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $EXEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

    SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

    5/8/24 4:11:20 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Exelixis Inc.

    SC 13G - EXELIXIS, INC. (0000939767) (Subject)

    2/13/24 9:19:48 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

    SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

    6/2/23 5:05:24 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care